SK100893A3 - Polyoxypropylene-polyoxyethylene copolymers with improved biological activity - Google Patents

Polyoxypropylene-polyoxyethylene copolymers with improved biological activity Download PDF

Info

Publication number
SK100893A3
SK100893A3 SK1008-93A SK100893A SK100893A3 SK 100893 A3 SK100893 A3 SK 100893A3 SK 100893 A SK100893 A SK 100893A SK 100893 A3 SK100893 A3 SK 100893A3
Authority
SK
Slovakia
Prior art keywords
copolymer
polyoxypropylene
polyoxyethylene
molecular weight
daltons
Prior art date
Application number
SK1008-93A
Other languages
English (en)
Slovak (sk)
Inventor
R Martin Emanuele
Robert L Hunter
Paula H Culbreth
Activity Logical
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27100911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK100893(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytrx Corp filed Critical Cytrx Corp
Publication of SK100893A3 publication Critical patent/SK100893A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/04—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers only
    • C08G65/06—Cyclic ethers having no atoms other than carbon and hydrogen outside the ring
    • C08G65/08—Saturated oxiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2603—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen
    • C08G65/2606—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups
    • C08G65/2609—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing oxygen containing hydroxyl groups containing aliphatic hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C08G65/2618—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen
    • C08G65/2621—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups
    • C08G65/2624—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds the other compounds containing nitrogen containing amine groups containing aliphatic amine groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Lubricants (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Materials For Medical Uses (AREA)
SK1008-93A 1991-03-19 1992-03-18 Polyoxypropylene-polyoxyethylene copolymers with improved biological activity SK100893A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67328991A 1991-03-19 1991-03-19
US84787492A 1992-03-13 1992-03-13
PCT/US1992/002254 WO1992016484A1 (fr) 1991-03-19 1992-03-18 Copolymeres de polyoxypropylene/polyoxyethylene presentant une activite biologique amelioree

Publications (1)

Publication Number Publication Date
SK100893A3 true SK100893A3 (en) 1994-04-06

Family

ID=27100911

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1008-93A SK100893A3 (en) 1991-03-19 1992-03-18 Polyoxypropylene-polyoxyethylene copolymers with improved biological activity

Country Status (19)

Country Link
US (7) US5523492A (fr)
EP (1) EP0576612B1 (fr)
JP (1) JP2647556B2 (fr)
KR (1) KR100224539B1 (fr)
CN (1) CN1069741A (fr)
AT (1) ATE187154T1 (fr)
AU (1) AU662146B2 (fr)
CA (1) CA2106474C (fr)
CZ (1) CZ194693A3 (fr)
DE (1) DE69230372T2 (fr)
DK (1) DK0576612T3 (fr)
ES (1) ES2140408T3 (fr)
GR (1) GR3032726T3 (fr)
HU (1) HUT67762A (fr)
IE (1) IE920860A1 (fr)
IL (1) IL101305A (fr)
NO (1) NO307890B1 (fr)
SK (1) SK100893A3 (fr)
WO (1) WO1992016484A1 (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
ES2140408T3 (es) * 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
WO1995010265A1 (fr) * 1993-10-15 1995-04-20 Cytrx Corporation Compositions d'apport therapeutique et leurs modes d'utilisation
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
EP1181937A3 (fr) 1994-08-09 2004-02-04 Cytrx Corporation Vaccin contenant des acides nucléiquées et adjuvant de vaccin
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
AU6358898A (en) * 1996-09-09 1998-04-17 Alexander V Kabanov Fluorinated copolymeric pharmaceutical adjuncts
US6312685B1 (en) 1998-03-13 2001-11-06 Timothy C. Fisher Red blood cells covalently bound with two different polyethylene glycol derivatives
US6942859B2 (en) 1998-03-13 2005-09-13 University Of Southern California Red blood cells covalently bound with polymers
WO2000021543A1 (fr) * 1998-10-09 2000-04-20 Cytrx Corporation Methode et composition permettant de traiter l'ischemie et la drepanocytose
CN1762990A (zh) * 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
WO2001093914A2 (fr) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Molecules a plate-forme polyvalentes comprenant un poly(ethylene oxyde) de poids moleculaire eleve
EP1335953A4 (fr) * 2000-06-23 2005-03-30 Merck & Co Inc Adjuvants de vaccins polynucleotidiques et formulations contenant des tensioactifs cationiques, procedes d'utilisation associes
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
CA2426582A1 (fr) * 2000-10-20 2002-08-08 Valentis, Inc. Preparations de diffusion de genes et methodes de traitement de pathologies ischemiques
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US6492881B2 (en) * 2001-01-31 2002-12-10 Compaq Information Technologies Group, L.P. Single to differential logic level interface for computer systems
EP1389121B1 (fr) 2001-04-24 2012-02-22 Purdue Research Foundation Procedes et compositions pour traiter des endommagements de tissu nerveux mammaire
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
BR0313060A (pt) * 2002-07-29 2005-06-28 Transform Pharmaceuticals Inc Composições farmacêuticas aquosas de 2,6-diisopropilfenol
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
AU2003293196A1 (en) * 2002-12-23 2004-07-29 Vical Incorporated Method for producing sterile polynucleotide based medicaments
US7521187B2 (en) * 2002-12-23 2009-04-21 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
AU2004224439B2 (en) 2003-03-24 2010-07-15 Genzyme Corporation Temporary embolization using inverse thermosensitive polymers
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
BRPI0413771A (pt) * 2003-09-05 2006-10-31 Ivy Animal Health Inc copolìmeros de polioxipropileno/polioietileno purificados e método de preparação dos mesmos
US20050143678A1 (en) 2003-10-14 2005-06-30 Pluromed, Inc. Confinement of kidney-stone fragments during lithotripsy
US7700086B2 (en) 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
JP4521547B2 (ja) * 2004-04-15 2010-08-11 株式会社サンメディカル技術研究所 血液ポンプの流量推定装置
WO2006060723A2 (fr) * 2004-12-03 2006-06-08 Vical Incorporated Procedes de production de copolymere sequence/particules amphiphiles
CA2599219C (fr) * 2005-02-25 2011-09-20 The Regents Of The University Of Michigan Compositions et methodes permettant de traiter et de prevenir la cardiomyopathie et les maladies cardiaques
EP1868652A2 (fr) 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Procede permettant de proteger des sites fonctionnels ou des epitopes sur des proteines
DK2601972T3 (en) 2005-05-02 2015-02-16 Genzyme Corp Kidney stone treatment without lithotripsy
WO2007008697A2 (fr) * 2005-07-08 2007-01-18 University Of Chicago Compositions et methodes pour le repliement de proteines denaturees
WO2008018892A2 (fr) * 2005-12-22 2008-02-14 Pluromed, Inc. Procédés et kits destinés à traiter des lacérations et des blessures par perforation utilisant des polymères thermosensitifs inverses
EP2012804A4 (fr) * 2006-04-24 2012-07-04 Bruce Medical Ab Agents anticancéreux à base de polymères
EP2046348B1 (fr) * 2006-08-01 2015-07-22 Phrixus Pharmaceuticals, Incorporated Utilisation d'un poloxamer pour la prevention et/ou le traitement de l'insuffisance cardiaque
WO2008033728A2 (fr) 2006-09-11 2008-03-20 Pluromed, Inc. Ballonnets et jupes d'occlusion atraumatiques et leurs méthodes d'utilisation
JP2010512230A (ja) * 2006-12-11 2010-04-22 プルーロームド インコーポレイテッド 灌流臓器止血法
EP2125092A4 (fr) * 2007-02-22 2012-03-14 Pluromed Inc Utilisation de polymères thermosensibles inverses pour contrôler l'écoulement d'un fluide biologique à la suite d'une procédure médicale
WO2008124088A2 (fr) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions et procédés pour le traitement de l'insuffisance cardiaque
US20110212047A1 (en) * 2007-08-10 2011-09-01 Synth Rx, Inc. Polymer Therapy for the Treatment of Chronic Microvascular Diseases
EP2612867A1 (fr) 2007-11-01 2013-07-10 Perseid Therapeutics LLC Acides nucléiques et polypeptides immunosuppresseurs
WO2009070793A1 (fr) 2007-11-29 2009-06-04 Pluromed, Inc. Résection muqueuse endoscopique utilisant des polymères thermosensibles inverses purifiés
US8852568B2 (en) * 2007-12-17 2014-10-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
CA2744100C (fr) 2008-10-21 2020-06-30 The General Hospital Corporation Transplantation de cellules
DE102008043343A1 (de) * 2008-10-31 2010-05-06 Evonik Goldschmidt Gmbh Silikonpolyetherblock-Copolymere mit definierter Polydispersität im Polyoxyalkylenteil und deren Verwendung als Stabilisatoren zur Herstellung von Polyurethanschäumen
WO2010072769A1 (fr) 2008-12-23 2010-07-01 Basf Se Procédé de production de copolymères à blocs polyéther
EP2490722A4 (fr) 2009-10-21 2014-03-05 Otonomy Inc Modulation de la température de gélification de formulations contenant des poloxamères
GB201008902D0 (en) * 2010-05-27 2010-07-14 Imp Innovations Ltd Membrane enhanced polymer sythesis
CN108504539B (zh) 2010-08-06 2021-11-02 通用医院公司以麻省总医院名义经营 用于细胞处理相关应用的系统和设备
KR20130097795A (ko) * 2010-11-15 2013-09-03 매스트 테라퓨틱스 인코포레이티드 위태로운 조직의 산소화 증강 방법
JP6388475B2 (ja) 2011-03-18 2018-09-12 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ グルコースポリマーを含む腹膜透析溶液
FR2977495B1 (fr) * 2011-07-07 2014-03-07 Sanofi Sa Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation
US9662345B2 (en) 2013-06-14 2017-05-30 Professional Compounding Centers Of America Antibiotic composition for inhalation and irrigation
EP3057598A1 (fr) 2013-10-16 2016-08-24 Mast Therapeutics, Inc. Modifications de volume plasmatique induites par un diurétique
JP6202471B2 (ja) 2013-10-31 2017-09-27 日油株式会社 医用ポリオキシプロピレン重合体の製造方法および医用ポリオキシプロピレン／ポリオキシエチレンブロック共重合体の製造方法
JP6747748B2 (ja) 2014-07-07 2020-08-26 ライフラフト バイオサイエンシーズ，インコーポレイテッド 長期循環物質のないポロクサマー組成物、その産生方法およびその使用
WO2016007542A1 (fr) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Thérapie de l'insuffisance cardiaque faisant appel à un poloxamère
US20160000823A1 (en) * 2014-07-07 2016-01-07 Mast Therapeutics, Inc. Methods and compositions for improving hemostasis
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
US20180353875A1 (en) * 2015-12-22 2018-12-13 Basf Se A process for purification of polyether block copolymers
US20200010618A1 (en) * 2017-02-09 2020-01-09 Basf Se A process for purification of polyether block copolymers
EP3728471A1 (fr) * 2017-12-21 2020-10-28 Sigma Aldrich Co. LLC Compositions de poloxamère et leurs procédés de préparation et d'utilisation
GB2579707A (en) 2018-10-15 2020-07-01 Avent Inc Compositions, systems, kits, and methods for neural ablation
WO2024160792A1 (fr) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Timbre transmucosal amélioré comprenant un cannabinoïde et/ou un opioïde

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
US2979528A (en) * 1953-10-19 1961-04-11 Wyandotte Chemicals Corp Nitrogen-containing polyoxyalkylene detergent compositions
US3022335A (en) * 1955-03-30 1962-02-20 Wyandotte Chemicals Corp Surface active polyoxyalkylene compounds having a plurality of heteric polyoxypropylene-polyoxyethylene chains
US2854378A (en) * 1955-12-08 1958-09-30 Bristol Lab Inc Tetracycline suppository
US3036118A (en) * 1957-09-11 1962-05-22 Wyandotte Chemicals Corp Mixtures of novel conjugated polyoxyethylene-polyoxypropylene compounds
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US3228834A (en) * 1962-06-08 1966-01-11 Hoffmann La Roche Pharmaceutical diluent compositions
US3140232A (en) * 1962-12-19 1964-07-07 Pfizer & Co C Color stabilization of tetracycline compositions with polypropylene glycols
US3391196A (en) * 1965-08-16 1968-07-02 Wyandotte Chemicals Corp High equivalent weight hydroxy-terminated ethylene oxide-butylene oxide polyether polyols
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3450502A (en) * 1967-09-25 1969-06-17 Wyandotte Chemicals Corp Method of operating heart-lung apparatus
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3867533A (en) * 1968-12-20 1975-02-18 Basf Wyandotte Corp Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US3577522A (en) * 1969-10-10 1971-05-04 Wyandotte Chemicals Corp Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3590125A (en) * 1969-10-10 1971-06-29 Wyandotte Chemicals Corp Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
CA959759A (en) * 1970-01-15 1974-12-24 John J. Miskel Method for absorption of drugs
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3997458A (en) * 1974-04-12 1976-12-14 Deknatel, Incorporated Method of cleansing contaminated wounds and surgical scrub solutions for same
US4104455A (en) * 1975-03-25 1978-08-01 Toyo Soda Manufacturing Co., Ltd. Polymerization of monomer
US4100271A (en) * 1976-02-26 1978-07-11 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4195167A (en) * 1976-05-28 1980-03-25 Union Carbide Corporation Gradient polymers of two or more cyclic, organic, ring-opening, addition polymerizable monomers and methods for making same
JPS545094A (en) 1977-06-09 1979-01-16 Tokyo Tanabe Co Production of pharmaceutical urokinase from contamination free human urine
DE2732929A1 (de) * 1977-07-21 1979-02-01 Bayer Ag Polyaether, verfahren zu ihrer herstellung sowie ihre verwendung als lipidabsorptionshemmer
DE2961374D1 (en) * 1978-01-27 1982-01-28 Bp Chem Int Ltd A method for increasing the selectivity to acetic acid in the production of a mixture of c1 to c3 monocarboxylic acids by oxidation of paraffinic hydrocarbons
DE2808865A1 (de) * 1978-03-02 1979-09-13 Hoechst Ag Mikrobiozide mittel auf der basis von alkyl-di-guanidinium-salzen
US4275244A (en) 1978-05-11 1981-06-23 Basf Wyandotte Corporation Linear polyalkylene ether glycols of high molecular weight
JPS5533194A (en) 1978-08-07 1980-03-08 Scholz D Thomas Stringgfastener device including tremolant
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
DE2850058A1 (de) * 1978-11-18 1980-05-29 Bayer Ag Polyaether-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2454409A1 (fr) * 1979-04-18 1980-11-14 Sovam Vehicule tracteur notamment pour avions gros porteurs
US4409209A (en) * 1979-10-12 1983-10-11 Ciba-Geigy Corporation Novel phosphorylmuramyl peptides and processes for the manufacture thereof
FI803077A7 (fi) * 1979-10-12 1981-04-13 Ciba Geigy Ag Foerfarande foer framstaellning av myramylpeptider
US4410660A (en) * 1980-05-05 1983-10-18 Montefiore Medical Center Binding assay for the detection of mycobacteria
US4575484A (en) * 1980-05-05 1986-03-11 Montefiore Medical Center, Inc. Binding assay for the detection of mycobacteria
US4489158A (en) * 1980-05-05 1984-12-18 Montefiore Hospital And Medical Center, Inc. Binding assay for the detection of mycobacteria
JPS578223A (en) * 1980-06-19 1982-01-16 Mitsui Petrochem Ind Ltd Production of alkylene oxide block copolymer
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4376118A (en) * 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
GR78246B (fr) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4395393A (en) * 1981-08-10 1983-07-26 Basf Wyandotte Corporation Artificial blood emulsifiers
US4407790A (en) * 1981-09-25 1983-10-04 Economics Laboratory, Inc. Method of controlling bloat using nonionic surfactants
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
DE3234084A1 (de) * 1982-09-14 1984-03-15 B. Braun Melsungen Ag, 3508 Melsungen Pharmazeutische zubereitungen zur behandlung von unerwuenschten verwachsungen sowie deren verwendung
SU1183112A1 (ru) * 1983-08-04 1985-10-07 Научно-Исследовательский Институт Экспериментальной И Клинической Терапии Министерства Здравоохранения Гсср Способ лечени острой ишемии миокарда
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4600652A (en) * 1985-04-01 1986-07-15 Warner-Lambert Company Permanently bonded antithrombogenic polyurethane surface
US5114708A (en) * 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US5183687A (en) * 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US4879109A (en) * 1986-05-15 1989-11-07 Emory University Method for treating burns
US5078995A (en) * 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5032394A (en) * 1986-05-15 1991-07-16 Emory University Method of treating burns
US4801452A (en) * 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5047236A (en) * 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5017370A (en) * 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
WO1987006831A1 (fr) * 1986-05-15 1987-11-19 Emory University Composition et procede de traitement d'un thrombus et d'un embolus
US5089260A (en) * 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
WO1987006836A1 (fr) * 1986-05-15 1987-11-19 Emory University Composition fibrinolytique
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5064643A (en) * 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US4837014A (en) * 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US4937070A (en) * 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5198211A (en) * 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5250294A (en) * 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US4997644A (en) * 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US4873083A (en) * 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5080894A (en) * 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
JP2527942B2 (ja) * 1986-09-18 1996-08-28 ティーディーケイ株式会社 磁気記録媒体
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US4764567A (en) 1986-11-20 1988-08-16 Basf Corporation Process for the preparation of polyoxyalkylene block polyethers having enhanced properties
WO1988006038A1 (fr) * 1987-02-20 1988-08-25 Emory University Composes anti-infectieux et procede d'utilisation
US5811088A (en) 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
JPH07109520B2 (ja) 1987-02-24 1995-11-22 株式会社リコー 電子写真用感光体
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DE4014923A1 (de) * 1990-05-10 1991-11-14 Basf Ag Verfahren zur herstellung von urethan- oder urethan- und isocyanuratgruppen enthaltenden hartschaumstoffen nach dem polyisocyanat-polyadditionsverfahren und die hierfuer geeigneten polyoxyalkylen-polyole
ES2140408T3 (es) * 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
US5294365A (en) * 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
US5371253A (en) * 1993-12-14 1994-12-06 Arco Chemical Technology, L.P. Process for producing esterified alkoxylated monoglycerides and diglycerides

Also Published As

Publication number Publication date
NO933337D0 (no) 1993-09-17
USRE36665E (en) 2000-04-18
DE69230372D1 (de) 2000-01-05
AU662146B2 (en) 1995-08-24
US5691387A (en) 1997-11-25
ATE187154T1 (de) 1999-12-15
EP0576612B1 (fr) 1999-12-01
CA2106474C (fr) 2004-02-10
IE920860A1 (en) 1992-09-23
IL101305A0 (en) 1992-11-15
HU9302628D0 (en) 1993-12-28
JP2647556B2 (ja) 1997-08-27
US5990241A (en) 1999-11-23
EP0576612A1 (fr) 1994-01-05
AU1773092A (en) 1992-10-21
CZ194693A3 (en) 1994-03-16
NO933337L (no) 1993-11-17
EP0576612A4 (fr) 1994-11-09
USRE37285E1 (en) 2001-07-17
IL101305A (en) 1995-11-27
NO307890B1 (no) 2000-06-13
KR100224539B1 (ko) 1999-10-15
US5523492A (en) 1996-06-04
CN1069741A (zh) 1993-03-10
GR3032726T3 (en) 2000-06-30
US6359014B1 (en) 2002-03-19
ES2140408T3 (es) 2000-03-01
DK0576612T3 (da) 2000-05-22
JPH06506258A (ja) 1994-07-14
US6747064B2 (en) 2004-06-08
CA2106474A1 (fr) 1992-09-20
WO1992016484A1 (fr) 1992-10-01
US20020183398A1 (en) 2002-12-05
HUT67762A (en) 1995-04-28
DE69230372T2 (de) 2000-06-15

Similar Documents

Publication Publication Date Title
SK100893A3 (en) Polyoxypropylene-polyoxyethylene copolymers with improved biological activity
US5696298A (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
IE83219B1 (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
EP0409940B1 (fr) Procedes et compositions servant au traitement des interactions hydrophobes pathologiques dans des fluides biologiques
Li et al. In situ gel-forming AP-57 peptide delivery system for cutaneous wound healing
Bradley et al. Biophysical consequences of linker chemistry and polymer size on stealth erythrocytes: size does matter
USRE38558E1 (en) Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
KR20170029562A (ko) 장기 순환 물질이 없는 폴록사머 조성물 및 이의 제조 방법 및 용도
EP3038603B1 (fr) Antidote synthetique polymérique
AU656224B2 (en) Method for treating vascular obstructions caused by abnormal cells
US20220354801A1 (en) Multifunctional Nanoparticles For Prevention And Treatment Of Atherosclerosis
WO2016007562A1 (fr) Méthodes et compositions permettant d'améliorer une hémostase
US6054492A (en) Fluorinated copolymeric pharmaceutical adjuncts
JP2005281665A (ja) 生体適合性を有する樹脂
US7863408B2 (en) Body fluid compatible and biocompatible resin
AU2020423624B2 (en) PEG-lipid
Gao et al. Protein-loaded comb-shape copolymer-based pH-responsive nanoparticles to improve the stability of proteins
Wen The chemical modification of hyperbranched polyglycerols for improved bioadhesive and hemostatic properties
Singh Biocompatible and biodegradable nanogels and hydrogels for protein/peptide delivery
Moghimi Recent developments and limitations of poloxamine-coated long-circulating particles in experimental drug delivery
Alizadeh Noghani Progesterone-binding modified hyperbranched polyglycerols: synthesis, characterization and biological assessment
US20080226725A1 (en) New and Advantageous Hydrogel Composition
HK1065713A1 (en) Sustained release hgf hydrogel preparations